Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics

Kyle LaHucik

Senior Reporter

Atea Pharmaceuticals, which went public in the fall of 2020 with the hopes of treating Covid-19 and other infectious diseases but has since struggled …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Atea con­firms un­so­licit­ed cash pro­pos­al from Tang Cap­i­tal’s Con­cen­tra, the shell buy­ing Jounce Ther­a­peu­tics

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Atea confirms unsolicited cash proposal from Tang Capital’s Concentra, the shell buying Jounce Therapeutics

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify